Category Archives: intellectual property

Windows and roofs ‘self-adapt’ to heating and cooling conditions

I have two items about thermochromic coatings. It’s a little confusing since the American Association for the Advancement of Science (AAAS), which publishes the journal featuring both papers has issued a news release that seemingly refers to both papers as a single piece of research.

Onto, the press/new releases from the research institutions to be followed by the AAAS news release.

Nanyang Technological University (NTU) does windows

A December 16, 2021 news item on Nanowerk announced work on energy-saving glass,

An international research team led by scientists from Nanyang Technological University, Singapore (NTU Singapore) has developed a material that, when coated on a glass window panel, can effectively self-adapt to heat or cool rooms across different climate zones in the world, helping to cut energy usage.

Developed by NTU researchers and reported in the journal Science (“Scalable thermochromic smart windows with passive radiative cooling regulation”), the first-of-its-kind glass automatically responds to changing temperatures by switching between heating and cooling.

The self-adaptive glass is developed using layers of vanadium dioxide nanoparticles composite, Poly(methyl methacrylate) (PMMA), and low-emissivity coating to form a unique structure which could modulate heating and cooling simultaneously.

A December 17, 2021 NTU press release (PDF), also on EurekAlert but published December 16, 2021, which originated the news item, delves further into the research (Note: A link has been removed),

The newly developed glass, which has no electrical components, works by exploiting the spectrums of light responsible for heating and cooling.

During summer, the glass suppresses solar heating (near infrared light), while boosting radiative cooling (long-wave infrared) – a natural phenomenon where heat emits through surfaces towards the cold universe – to cool the room. In the winter, it does the opposite to warm up the room.

In lab tests using an infrared camera to visualise results, the glass allowed a controlled amount of heat to emit in various conditions (room temperature – above 70°C), proving its ability to react dynamically to changing weather conditions.

New glass regulates both heating and cooling

Windows are one of the key components in a building’s design, but they are also the least energy-efficient and most complicated part. In the United States alone, window-associated energy consumption (heating and cooling) in buildings accounts for approximately four per cent of their total primary energy usage each year according to an estimation based on data available from the Department of Energy in US.[1]

While scientists elsewhere have developed sustainable innovations to ease this energy demand – such as using low emissivity coatings to prevent heat transfer and electrochromic glass that regulate solar transmission from entering the room by becoming tinted – none of the solutions have been able to modulate both heating and cooling at the same time, until now.

The principal investigator of the study, Dr Long Yi of the NTU School of Materials Science and Engineering (MSE) said, “Most energy-saving windows today tackle the part of solar heat gain caused by visible and near infrared sunlight. However, researchers often overlook the radiative cooling in the long wavelength infrared. While innovations focusing on radiative cooling have been used on walls and roofs, this function becomes undesirable during winter. Our team has demonstrated for the first time a glass that can respond favourably to both wavelengths, meaning that it can continuously self-tune to react to a changing temperature across all seasons.”

As a result of these features, the NTU research team believes their innovation offers a convenient way to conserve energy in buildings since it does not rely on any moving components, electrical mechanisms, or blocking views, to function.

To improve the performance of windows, the simultaneous modulation of both solar transmission and radiative cooling are crucial, said co-authors Professor Gang Tan from The University of Wyoming, USA, and Professor Ronggui Yang from the Huazhong University of Science and Technology, Wuhan, China, who led the building energy saving simulation.

“This innovation fills the missing gap between traditional smart windows and radiative cooling by paving a new research direction to minimise energy consumption,” said Prof Gang Tan.

The study is an example of groundbreaking research that supports the NTU 2025 strategic plan, which seeks to address humanity’s grand challenges on sustainability, and accelerate the translation of research discoveries into innovations that mitigate human impact on the environment.

Innovation useful for a wide range of climate types

As a proof of concept, the scientists tested the energy-saving performance of their invention using simulations of climate data covering all populated parts of the globe (seven climate zones).

The team found the glass they developed showed energy savings in both warm and cool seasons, with an overall energy saving performance of up to 9.5%, or ~330,000 kWh per year (estimated energy required to power 60 household in Singapore for a year) less than commercially available low emissivity glass in a simulated medium sized office building.

First author of the study Wang Shancheng, who is Research Fellow and former PhD student of Dr Long Yi, said, “The results prove the viability of applying our glass in all types of climates as it is able to help cut energy use regardless of hot and cold seasonal temperature fluctuations. This sets our invention apart from current energy-saving windows which tend to find limited use in regions with less seasonal variations.”

Moreover, the heating and cooling performance of their glass can be customised to suit the needs of the market and region for which it is intended.

“We can do so by simply adjusting the structure and composition of special nanocomposite coating layered onto the glass panel, allowing our innovation to be potentially used across a wide range of heat regulating applications, and not limited to windows,” Dr Long Yi said.

Providing an independent view, Professor Liangbing Hu, Herbert Rabin Distinguished Professor, Director of the Center for Materials Innovation at the University of Maryland, USA, said, “Long and co-workers made the original development of smart windows that can regulate the near-infrared sunlight and the long-wave infrared heat. The use of this smart window could be highly important for building energy-saving and decarbonization.”  

A Singapore patent has been filed for the innovation. As the next steps, the research team is aiming to achieve even higher energy-saving performance by working on the design of their nanocomposite coating.

The international research team also includes scientists from Nanjing Tech University, China. The study is supported by the Singapore-HUJ Alliance for Research and Enterprise (SHARE), under the Campus for Research Excellence and Technological Enterprise (CREATE) programme, Minster of Education Research Fund Tier 1, and the Sino-Singapore International Joint Research Institute.

Here’s a link to and a citation for the paper,

Scalable thermochromic smart windows with passive radiative cooling regulation by Shancheng Wang, Tengyao Jiang, Yun Meng, Ronggui Yang, Gang Tan, and Yi Long. Science • 16 Dec 2021 • Vol 374, Issue 6574 • pp. 1501-1504 • DOI: 10.1126/science.abg0291

This paper is behind a paywall.

Lawrence Berkeley National Laboratory (Berkeley Lab; LBNL) does roofs

A December 16, 2021 Lawrence Berkeley National Laboratory news release (also on EurekAlert) announces an energy-saving coating for roofs (Note: Links have been removed),

Scientists have developed an all-season smart-roof coating that keeps homes warm during the winter and cool during the summer without consuming natural gas or electricity. Research findings reported in the journal Science point to a groundbreaking technology that outperforms commercial cool-roof systems in energy savings.

“Our all-season roof coating automatically switches from keeping you cool to warm, depending on outdoor air temperature. This is energy-free, emission-free air conditioning and heating, all in one device,” said Junqiao Wu, a faculty scientist in Berkeley Lab’s Materials Sciences Division and a UC Berkeley professor of materials science and engineering who led the study.

Today’s cool roof systems, such as reflective coatings, membranes, shingles, or tiles, have light-colored or darker “cool-colored” surfaces that cool homes by reflecting sunlight. These systems also emit some of the absorbed solar heat as thermal-infrared radiation; in this natural process known as radiative cooling, thermal-infrared light is radiated away from the surface.

The problem with many cool-roof systems currently on the market is that they continue to radiate heat in the winter, which drives up heating costs, Wu explained.

“Our new material – called a temperature-adaptive radiative coating or TARC – can enable energy savings by automatically turning off the radiative cooling in the winter, overcoming the problem of overcooling,” he said.

A roof for all seasons

Metals are typically good conductors of electricity and heat. In 2017, Wu and his research team discovered that electrons in vanadium dioxide behave like a metal to electricity but an insulator to heat – in other words, they conduct electricity well without conducting much heat. “This behavior contrasts with most other metals where electrons conduct heat and electricity proportionally,” Wu explained.

Vanadium dioxide below about 67 degrees Celsius (153 degrees Fahrenheit) is also transparent to (and hence not absorptive of) thermal-infrared light. But once vanadium dioxide reaches 67 degrees Celsius, it switches to a metal state, becoming absorptive of thermal-infrared light. This ability to switch from one phase to another – in this case, from an insulator to a metal – is characteristic of what’s known as a phase-change material.

To see how vanadium dioxide would perform in a roof system, Wu and his team engineered a 2-centimeter-by-2-centimeter TARC thin-film device.

TARC “looks like Scotch tape, and can be affixed to a solid surface like a rooftop,” Wu said.

In a key experiment, co-lead author Kechao Tang set up a rooftop experiment at Wu’s East Bay home last summer to demonstrate the technology’s viability in a real-world environment.

A wireless measurement device set up on Wu’s balcony continuously recorded responses to changes in direct sunlight and outdoor temperature from a TARC sample, a commercial dark roof sample, and a commercial white roof sample over multiple days.

How TARC outperforms in energy savings

The researchers then used data from the experiment to simulate how TARC would perform year-round in cities representing 15 different climate zones across the continental U.S.

Wu enlisted Ronnen Levinson, a co-author on the study who is a staff scientist and leader of the Heat Island Group in Berkeley Lab’s Energy Technologies Area, to help them refine their model of roof surface temperature. Levinson developed a method to estimate TARC energy savings from a set of more than 100,000 building energy simulations that the Heat Island Group previously performed to evaluate the benefits of cool roofs and cool walls across the United States.

Finnegan Reichertz, a 12th grade student at the East Bay Innovation Academy in Oakland who worked remotely as a summer intern for Wu last year, helped to simulate how TARC and the other roof materials would perform at specific times and on specific days throughout the year for each of the 15 cities or climate zones the researchers studied for the paper.

The researchers found that TARC outperforms existing roof coatings for energy saving in 12 of the 15 climate zones, particularly in regions with wide temperature variations between day and night, such as the San Francisco Bay Area, or between winter and summer, such as New York City.

“With TARC installed, the average household in the U.S. could save up to 10% electricity,” said Tang, who was a postdoctoral researcher in the Wu lab at the time of the study. He is now an assistant professor at Peking University in Beijing, China.

Standard cool roofs have high solar reflectance and high thermal emittance (the ability to release heat by emitting thermal-infrared radiation) even in cool weather.

According to the researchers’ measurements, TARC reflects around 75% of sunlight year-round, but its thermal emittance is high (about 90%) when the ambient temperature is warm (above 25 degrees Celsius or 77 degrees Fahrenheit), promoting heat loss to the sky. In cooler weather, TARC’s thermal emittance automatically switches to low, helping to retain heat from solar absorption and indoor heating, Levinson said.

Findings from infrared spectroscopy experiments using advanced tools at Berkeley Lab’s Molecular Foundry validated the simulations.

“Simple physics predicted TARC would work, but we were surprised it would work so well,” said Wu. “We originally thought the switch from warming to cooling wouldn’t be so dramatic. Our simulations, outdoor experiments, and lab experiments proved otherwise – it’s really exciting.”

The researchers plan to develop TARC prototypes on a larger scale to further test its performance as a practical roof coating. Wu said that TARC may also have potential as a thermally protective coating to prolong battery life in smartphones and laptops, and shield satellites and cars from extremely high or low temperatures. It could also be used to make temperature-regulating fabric for tents, greenhouse coverings, and even hats and jackets.

Co-lead authors on the study were Kaichen Dong and Jiachen Li.

The Molecular Foundry is a nanoscience user facility at Berkeley Lab.

This work was primarily supported by the DOE Office of Science and a Bakar Fellowship.

The technology is available for licensing and collaboration. If interested, please contact Berkeley Lab’s Intellectual Property Office, ipo@lbl.gov.

Here’s a link to and a citation for the paper,

Temperature-adaptive radiative coating for all-season household thermal regulation by Kechao Tang, Kaichen Dong, Jiachen Li, Madeleine P. Gordon, Finnegan G. Reichertz, Hyungjin Kim, Yoonsoo Rho, Qingjun Wang, Chang-Yu Lin, Costas P. Grigoropoulos, Ali Javey, Jeffrey J. Urban, Jie Yao, Ronnen Levinson, Junqiao Wu. Science • 16 Dec 2021 • Vol 374, Issue 6574 • pp. 1504-1509 • DOI: 10.1126/science.abf7136

This paper is behind a paywall.

An interesting news release from the AAAS

While it’s a little confusing as it cites only the ‘window’ research from NTU, the body of this news release offers some additional information about the usefulness of thermochromic materials and seemingly refers to both papers, from a December 16, 2021 AAAS news release,

Temperature-adaptive passive radiative cooling for roofs and windows

When it’s cold out, window glass and roof coatings that use passive radiative cooling to keep buildings cool can be designed to passively turn off radiative cooling to avoid heat loss, two new studies show.  Their proof-of-concept analyses demonstrate that passive radiative cooling can be expanded to warm and cold climate applications and regions, potentially providing all-season energy savings worldwide. Buildings consume roughly 40% of global energy, a large proportion of which is used to keep them cool in warmer climates. However, most temperature regulation systems commonly employed are not very energy efficient and require external power or resources. In contrast, passive radiative cooling technologies, which use outer space as a near-limitless natural heat sink, have been extensively examined as a means of energy-efficient cooling for buildings. This technology uses materials designed to selectively emit narrow-band radiation through the infrared atmospheric window to disperse heat energy into the coldness of space. However, while this approach has proven effective in cooling buildings to below ambient temperatures, it is only helpful during the warmer months or in regions that are perpetually hot. Furthermore, the inability to “turn off” passive cooling in cooler climes or in regions with large seasonal temperature variations means that continuous cooling during colder periods would exacerbate the energy costs of heating. In two different studies, by Shancheng Wang and colleagues and Kechao Tang and colleagues, researchers approach passive radiative cooling from an all-season perspective and present a new, scalable temperature-adaptive radiative technology that passively turns off radiative cooling at lower temperatures. Wang et al. and Tang et al. achieve this using a tungsten-doped vanadium dioxide and show how it can be applied to create both window glass and a flexible roof coating, respectively. Model simulations of the self-adapting materials suggest they could provide year-round energy savings across most climate zones, especially those with substantial seasonal temperature variations. 

I wish them all good luck with getting these materials to market.

Combine a nonwoven nanotextile and unique compounds to treat skin infections

A September 30, 2021 news item on Nanowerk a new material for treating skin infections (Note: A link has been removed),

Researchers at the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague) and the Technical University of Liberec in collaboration with researchers from the Institute of Microbiology of the CAS, the Department of Burns Medicine of the Third Faculty of Medicine at Charles University (Czech Republic), and P. J. Šafárik University in Košice (Slovakia) have developed a novel antibacterial material combining nonwoven nanotextile and unique compounds with antibacterial properties (Scientific Reports, “Novel lipophosphonoxin-loaded polycaprolactone electrospun nanofiber dressing reduces Staphylococcus aureus induced wound infection in mice”).

A September 30, 2021 Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) press release (also on EurekAlert), which originated the news item, describes the work in more detail,

Because the number of bacterial strains resistant to common antibiotics is steadily increasing, there is a growing need for new substances with antibacterial properties. A very promising class of substances are the so-called lipophosphonoxins (LPPO) developed by the team of Dominik Rejman of IOCB Prague in collaboration with Libor Krásný of the Institute of Microbiology of the CAS.

“Lipophosphonoxins hold considerable promise as a new generation of antibiotics. They don’t have to penetrate the bacteria but instead act on the surface, where they disrupt the bacterial cell membrane. That makes them very efficient at destroying bacteria,” says Rejman.

“A big advantage of LPPO is the limited ability of bacteria to develop resistance to them. In an experiment lasting several weeks, we failed to find a bacteria resistant to these substances, while resistance to well-known antibiotics developed relatively easily,” explains Krásný.

The potential of LPPO is especially evident in situations requiring immediate targeted intervention, such as skin infections. Here, however, the substances must be combined with a suitable material that ensures their topical efficacy without the need to enter the circulatory system. This reduces the burden to the body and facilitates use.

One such suitable material is a polymer nanofiber developed by the team of David Lukáš of the Faculty of Science, Humanities and Education at the Technical University of Liberec. The researchers combined it with LPPO to prepare a new type of dressing material for bacteria-infected skin wounds. The material’s main benefit is that the antibacterial LPPO are released from it gradually and in relation to the presence and extent of infection.

“The research and development of the material NANO-LPPO is a continuation of the work carried out in a clinical trial on the NANOTARDIS medical device, which we recently successfully completed in collaboration with Regional Hospital Liberec, University Hospital Královské Vinohrady, and Bulovka University Hospital. With its morphological and physical-chemical properties, the device promotes the healing of clean acute wounds,” says Lukáš. “This collaboration with colleagues from IOCB Prague is really advancing the possibilities for use of functionalized nanofiber materials in the areas of chronic and infected wounds.”

“Enzymes decompose the nanomaterial into harmless molecules. The LPPO are an integral component of the material and are primarily released from it during this decomposition. Moreover, the process is greatly accelerated by the presence of bacteria, which produce lytic enzymes. This means that the more bacteria there are in the wound, the faster the material decomposes, which in turn releases more of the active substances into the affected site to promote healing and regeneration of soft tissues,” says Rejman in describing the action of the material.  

“Our experiments on mice confirmed the ability of NANO-LPPO to prevent infection in the wound and thus accelerate healing and regeneration. There was practically no spread of infection where we used the material. If clinical trials go well, this could be a breakthrough in the treatment of burns and other serious injuries where infection poses an acute threat and complication to treatment,” explains wound care specialist Peter Gál of the Department of Burns Medicine at Charles University’s Third Faculty of Medicine, the Faculty of Medicine at P. J. Šafárik University in Košice, and the East Slovak Institute for Cardiovascular Diseases.  

In terms of applications, NANO-LPPO is an interesting material for manufacturers of medicinal products and medical devices. Its commercialization is being coordinated through a collaborative effort between IOCB TECH, a subsidiary of IOCB Prague, and Charles University Innovations Prague, a subsidiary of Charles University, both of which were created for the purpose of transferring results of academic research to practice. The companies are currently seeking a suitable commercial partner.

Here’s a link to and a citation for the paper,

Novel lipophosphonoxin-loaded polycaprolactone electrospun nanofiber dressing reduces Staphylococcus aureus induced wound infection in mice by Duy Dinh Do Pham, Věra Jenčová, Miriam Kaňuchová, Jan Bayram, Ivana Grossová, Hubert Šuca, Lukáš Urban, Kristýna Havlíčková, Vít Novotný, Petr Mikeš, Viktor Mojr, Nikifor Asatiani, Eva Kuželová Košťáková, Martina Maixnerová, Alena Vlková, Dragana Vítovská, Hana Šanderová, Alexandr Nemec, Libor Krásný, Robert Zajíček, David Lukáš, Dominik Rejman & Peter Gál. Scientific Reports volume 11, Article number: 17688 (2021) DOI: https://doi.org/10.1038/s41598-021-96980-7 Published: 03 September 2021

This paper is open access.

Soft, inflatable, and potentially low-cost neuroprosthetic hand?

An August 16, 2021 news item on ScienceDaily describes a new type of neuroprosthetic,

For the more than 5 million people in the world who have undergone an upper-limb amputation, prosthetics have come a long way. Beyond traditional mannequin-like appendages, there is a growing number of commercial neuroprosthetics — highly articulated bionic limbs, engineered to sense a user’s residual muscle signals and robotically mimic their intended motions.

But this high-tech dexterity comes at a price. Neuroprosthetics can cost tens of thousands of dollars and are built around metal skeletons, with electrical motors that can be heavy and rigid.

Now engineers at MIT [Massachusetts Institute of Technology] and Shanghai Jiao Tong University have designed a soft, lightweight, and potentially low-cost neuroprosthetic hand. Amputees who tested the artificial limb performed daily activities, such as zipping a suitcase, pouring a carton of juice, and petting a cat, just as well as — and in some cases better than — those with more rigid neuroprosthetics.

Here’s a video demonstration,

An August 16, 2021 MIT news news release (also on EurekAlert), which originated the news item, provides more detail,

The researchers found the prosthetic, designed with a system for tactile feedback, restored some primitive sensation in a volunteer’s residual limb. The new design is also surprisingly durable, quickly recovering after being struck with a hammer or run over with a car.

The smart hand is soft and elastic, and weighs about half a pound. Its components total around $500 — a fraction of the weight and material cost associated with more rigid smart limbs.

“This is not a product yet, but the performance is already similar or superior to existing neuroprosthetics, which we’re excited about,” says Xuanhe Zhao, professor of mechanical engineering and of civil and environmental engineering at MIT. “There’s huge potential to make this soft prosthetic very low cost, for low-income families who have suffered from amputation.”

Zhao and his colleagues have published their work today [August 16, 2021] in Nature Biomedical Engineering. Co-authors include MIT postdoc Shaoting Lin, along with Guoying Gu, Xiangyang Zhu, and collaborators at Shanghai Jiao Tong University in China.

Big Hero hand

The team’s pliable new design bears an uncanny resemblance to a certain inflatable robot in the animated film “Big Hero 6.” Like the squishy android, the team’s artificial hand is made from soft, stretchy material — in this case, the commercial elastomer EcoFlex. The prosthetic comprises five balloon-like fingers, each embedded with segments of fiber, similar to articulated bones in actual fingers. The bendy digits are connected to a 3-D-printed “palm,” shaped like a human hand.

Rather than controlling each finger using mounted electrical motors, as most neuroprosthetics do, the researchers used a simple pneumatic system to precisely inflate fingers and bend them in specific positions. This system, including a small pump and valves, can be worn at the waist, significantly reducing the prosthetic’s weight.

Lin developed a computer model to relate a finger’s desired position to the corresponding pressure a pump would have to apply to achieve that position. Using this model, the team developed a controller that directs the pneumatic system to inflate the fingers, in positions that mimic five common grasps, including pinching two and three fingers together, making a balled-up fist, and cupping the palm.

The pneumatic system receives signals from EMG sensors — electromyography sensors that measure electrical signals generated by motor neurons to control muscles. The sensors are fitted at the prosthetic’s opening, where it attaches to a user’s limb. In this arrangement, the sensors can pick up signals from a residual limb, such as when an amputee imagines making a fist.

The team then used an existing algorithm that “decodes” muscle signals and relates them to common grasp types. They used this algorithm to program the controller for their pneumatic system. When an amputee imagines, for instance, holding a wine glass, the sensors pick up the residual muscle signals, which the controller then translates into corresponding pressures. The pump then applies those pressures to inflate each finger and produce the amputee’s intended grasp.

Going a step further in their design, the researchers looked to enable tactile feedback — a feature that is not incorporated in most commercial neuroprosthetics. To do this, they stitched to each fingertip a pressure sensor, which when touched or squeezed produces an electrical signal proportional to the sensed pressure. Each sensor is wired to a specific location on an amputee’s residual limb, so the user can “feel” when the prosthetic’s thumb is pressed, for example, versus the forefinger.

Good grip

To test the inflatable hand, the researchers enlisted two volunteers, each with upper-limb amputations. Once outfitted with the neuroprosthetic, the volunteers learned to use it by repeatedly contracting the muscles in their arm while imagining making five common grasps.

After completing this 15-minute training, the volunteers were asked to perform a number of standardized tests to demonstrate manual strength and dexterity. These tasks included stacking checkers, turning pages, writing with a pen, lifting heavy balls, and picking up fragile objects like strawberries and bread. They repeated the same tests using a more rigid, commercially available bionic hand and found that the inflatable prosthetic was as good, or even better, at most tasks, compared to its rigid counterpart.

One volunteer was also able to intuitively use the soft prosthetic in daily activities, for instance to eat food like crackers, cake, and apples, and to handle objects and tools, such as laptops, bottles, hammers, and pliers. This volunteer could also safely manipulate the squishy prosthetic, for instance to shake someone’s hand, touch a flower, and pet a cat.

In a particularly exciting exercise, the researchers blindfolded the volunteer and found he could discern which prosthetic finger they poked and brushed. He was also able to “feel” bottles of different sizes that were placed in the prosthetic hand, and lifted them in response. The team sees these experiments as a promising sign that amputees can regain a form of sensation and real-time control with the inflatable hand.

The team has filed a patent on the design, through MIT, and is working to improve its sensing and range of motion.

“We now have four grasp types. There can be more,” Zhao says. “This design can be improved, with better decoding technology, higher-density myoelectric arrays, and a more compact pump that could be worn on the wrist. We also want to customize the design for mass production, so we can translate soft robotic technology to benefit society.”

Here’s a link to and a citation for the paper,

A soft neuroprosthetic hand providing simultaneous myoelectric control and tactile feedback by Guoying Gu, Ningbin Zhang, Haipeng Xu, Shaoting Lin, Yang Yu, Guohong Chai, Lisen Ge, Houle Yang, Qiwen Shao, Xinjun Sheng, Xiangyang Zhu, Xuanhe Zhao. Nature Biomedical Engineering (2021) DOI: https://doi.org/10.1038/s41551-021-00767-0 Published: 16 August 2021

This paper is behind a paywall.

The coolest paint

It’s the ‘est’ of it all. The coolest, the whitest, the blackest … Scientists and artists are both pursuing the ‘est’. (More about the pursuit later in this posting.)

In this case, scientists have developed the coolest, whitest paint yet. From an April 16, 2021 news item on Nanowerk,

In an effort to curb global warming, Purdue University engineers have created the whitest paint yet. Coating buildings with this paint may one day cool them off enough to reduce the need for air conditioning, the researchers say.

In October [2020], the team created an ultra-white paint that pushed limits on how white paint can be. Now they’ve outdone that. The newer paint not only is whiter but also can keep surfaces cooler than the formulation that the researchers had previously demonstrated.

“If you were to use this paint to cover a roof area of about 1,000 square feet, we estimate that you could get a cooling power of 10 kilowatts. That’s more powerful than the central air conditioners used by most houses,” said Xiulin Ruan, a Purdue professor of mechanical engineering.

Caption: Xiulin Ruan, a Purdue University professor of mechanical engineering, holds up his lab’s sample of the whitest paint on record. Credit: Purdue University/Jared Pike

This is nicely done. Researcher Xiulin Ruan is standing close to a structure that could be said to resemble the sun while in shirtsleeves and sunglasses and holding up a sample of his whitest paint in April (not usually a warm month in Indiana).

An April 15, 2021 Purdue University news release (also on EurkeAlert), which originated the news item, provides more detail about the work and hints about its commercial applications both civilian and military,

The researchers believe that this white may be the closest equivalent of the blackest black, “Vantablack,” [emphasis mine; see comments later in this post] which absorbs up to 99.9% of visible light. The new whitest paint formulation reflects up to 98.1% of sunlight – compared with the 95.5% of sunlight reflected by the researchers’ previous ultra-white paint – and sends infrared heat away from a surface at the same time.

Typical commercial white paint gets warmer rather than cooler. Paints on the market that are designed to reject heat reflect only 80%-90% of sunlight and can’t make surfaces cooler than their surroundings.

The team’s research paper showing how the paint works publishes Thursday (April 15 [2021]) as the cover of the journal ACS Applied Materials & Interfaces.

What makes the whitest paint so white

Two features give the paint its extreme whiteness. One is the paint’s very high concentration of a chemical compound called barium sulfate [emphasis mine] which is also used to make photo paper and cosmetics white.

“We looked at various commercial products, basically anything that’s white,” said Xiangyu Li, a postdoctoral researcher at the Massachusetts Institute of Technology who worked on this project as a Purdue Ph.D. student in Ruan’s lab. “We found that using barium sulfate, you can theoretically make things really, really reflective, which means that they’re really, really white.”

The second feature is that the barium sulfate particles are all different sizes in the paint. How much each particle scatters light depends on its size, so a wider range of particle sizes allows the paint to scatter more of the light spectrum from the sun.

“A high concentration of particles that are also different sizes gives the paint the broadest spectral scattering, which contributes to the highest reflectance,” said Joseph Peoples, a Purdue Ph.D. student in mechanical engineering.

There is a little bit of room to make the paint whiter, but not much without compromising the paint.”Although a higher particle concentration is better for making something white, you can’t increase the concentration too much. The higher the concentration, the easier it is for the paint to break or peel off,” Li said.

How the whitest paint is also the coolest

The paint’s whiteness also means that the paint is the coolest on record. Using high-accuracy temperature reading equipment called thermocouples, the researchers demonstrated outdoors that the paint can keep surfaces 19 degrees Fahrenheit cooler than their ambient surroundings at night. It can also cool surfaces 8 degrees Fahrenheit below their surroundings under strong sunlight during noon hours.

The paint’s solar reflectance is so effective, it even worked in the middle of winter. During an outdoor test with an ambient temperature of 43 degrees Fahrenheit, the paint still managed to lower the sample temperature by 18 degrees Fahrenheit.

This white paint is the result of six years of research building on attempts going back to the 1970s to develop radiative cooling paint as a feasible alternative to traditional air conditioners.

Ruan’s lab had considered over 100 different materials, narrowed them down to 10 and tested about 50 different formulations for each material. Their previous whitest paint was a formulation made of calcium carbonate, an earth-abundant compound commonly found in rocks and seashells.

The researchers showed in their study that like commercial paint, their barium sulfate-based paint can potentially handle outdoor conditions. The technique that the researchers used to create the paint also is compatible with the commercial paint fabrication process.

Patent applications for this paint formulation have been filed through the Purdue Research Foundation Office of Technology Commercialization. This research was supported by the Cooling Technologies Research Center at Purdue University and the Air Force Office of Scientific Research [emphasis mine] through the Defense University Research Instrumentation Program (Grant No.427 FA9550-17-1-0368). The research was performed at Purdue’s FLEX Lab and Ray W. Herrick Laboratories and the Birck Nanotechnology Center of Purdue’s Discovery Park.

Here’s a link to and a citation for the paper,

Ultrawhite BaSO4 Paints and Films for Remarkable Daytime Subambient Radiative Cooling by Xiangyu Li, Joseph Peoples, Peiyan Yao, and Xiulin Ruan. ACS Appl. Mater. Interfaces 2021, XXXX, XXX, XXX-XXX DOI: https://doi.org/10.1021/acsami.1c02368 Publication Date:April 15, 2021 © 2021 American Chemical Society

This paper is behind a paywall.

Vantablack and the ongoing ‘est’ of blackest

Vantablack’s 99.9% light absorption no longer qualifies it for the ‘blackest black’. A newer standard for the ‘blackest black’ was set by the US National Institute of Standards and Technology at 99.99% light absorption with its N.I.S.T. ultra-black in 2019, although that too seems to have been bested.

I have three postings covering the Vantablack and blackest black story,

The third posting (December 2019) provides a brief summary of the story along with what was the latest from the US National Institute of Standards and Technology. There’s also a little bit about the ‘The Redemption of Vanity’ an art piece demonstrating the blackest black material from the Massachusetts Institute of Technology, which they state has 99.995% (at least) absorption of light.

From a science perspective, the blackest black would be useful for space exploration.

I am surprised there doesn’t seem to have been an artistic rush to work with the whitest white. That impression may be due to the fact that the feuds get more attention than quiet work.

Dark side to the whitest white?

Andrew Parnell, research fellow in physics and astronomy at the University of Sheffield (UK), mentions a downside to obtaining the material needed to produce this cooling white paint in a June 10, 2021 essay on The Conversation (h/t Fast Company), Note: Links have been removed,

… this whiter-than-white paint has a darker side. The energy required to dig up raw barite ore to produce and process the barium sulphite that makes up nearly 60% of the paint means it has a huge carbon footprint. And using the paint widely would mean a dramatic increase in the mining of barium.

Parnell ends his essay with this (Note: Links have been removed),

Barium sulphite-based paint is just one way to improve the reflectivity of buildings. I’ve spent the last few years researching the colour white in the natural world, from white surfaces to white animals. Animal hairs, feathers and butterfly wings provide different examples of how nature regulates temperature within a structure. Mimicking these natural techniques could help to keep our cities cooler with less cost to the environment.

The wings of one intensely white beetle species called Lepidiota stigma appear a strikingly bright white thanks to nanostructures in their scales, which are very good at scattering incoming light. This natural light-scattering property can be used to design even better paints: for example, by using recycled plastic to create white paint containing similar nanostructures with a far lower carbon footprint. When it comes to taking inspiration from nature, the sky’s the limit.

Who’s running the life science companies’ public relations campaign in British Columbia (Vancouver, Canada)?

I started writing this in the aftermath of the 2021 Canadian federal budget when most of the action (so far) occurred but if you keep going to the end of this post you’ll find updates for Precision Nanosystems and AcCellera and a few extra bits. Also, you may want to check out my August 20, 2021 posting (Getting erased from the mRNA/COVID-19 story) about Ian MacLachlan and some of the ‘rough and tumble’ of the biotechnology scene in BC/Canada. Now, onto my analysis of the life sciences public relations campaign in British Columbia.

Gordon Hoekstra’s May 7, 2021 article (also in print on May 8, 2021) about the British Columbia (mostly in Vancouver) biotechnology scene in the Vancouver Sun is the starting point for this story.

His entry (whether the reporter realizes it or not) into a communications (or public relations) campaign spanning federal, provincial, and municipal jurisdictions is well written and quite informative. While it’s tempting to attribute the whole thing to a single evil genius or mastermind in answer to the question posed in the head, the ‘campaign’ is likely a targeted effort by one or more groups and individuals enhanced with a little luck.

Federal and provincial money for life sciences and technology

The Business Council of British Columbia’s April 22, 2021 Federal & B.C. Budgets 2021 Analysis (PDF), notes this in its Highlights section,

•Another priority reflected in both budgets is boosting innovation and accelerating the growth of technology-producing companies. The federal budget [April 19, 2021] is spending billions more to support the life sciences and bio-manufacturing industry, clean technologies, the development of electric vehicles, the aerospace sector, quantum computing, AI, genomics, and digital technologies, among others.

•B.C.’s budget [April 20, 2021] also provides funding to spur innovation, support the technology sector and grow locally-based companies. In this area the main item is the new InBC Investment Corporation [emphasis mine], first announced last summer. Endowed with $500 million financed via an agency loan, the Corporation will establish a fund to invest in growing and “anchoring” high-growth [emphasis mine] B.C. businesses.

Their in-depth analysis does not provide more detail about the life sciences investments in the 2021 Canadian federal budget or the 2021 BC provincial budget.

My May 4, 2021 posting details many of the Canadian federal investments in life sciences and other technology areas of interest. The 2021 BC budget announcement is so vague, it didn’t merit much more than this mention until now.

InBC Investment Corporation (BC’s contribution)

InBC Investment Corporation was set up on or about April 27, 2021 as three news ‘references’ (brief summaries with a link) suggest: InBC Investment Corp. Act, InBC Announcement, $500-million investment fund paves way for StrongerBC.

While the corporation does not have a specific mandate to fund the biotechnology sector, given the current enthusiasm, it’s easy to believe they might be more inclined to fund them than not, regardless of any expertise they or may not have specifically in that field.

Of most interest to me was InBC’s Board of Directors, which I tracked down to a BC Ministry of Jobs, Economic Recovery and Innovation May 6, 2021 news release,

InBC Investment Corp. now has a full board of directors with backgrounds in finance, economics, impact investing and business to provide strategic guidance and accountability for the new Crown corporation.

InBC will support startups [emphasis mine], help promising companies scale up and work with a “triple bottom line” mandate that considers people, the planet and profits, to position British Columbia as a front-runner in the post-pandemic economy.

Christine Bergeron, president and chief executive officer of Vancity, will serve as the new board chair of InBC Investment Corp. The nine-member board of directors is made up of both public and private sector members who are responsible for oversight of the corporation, including its mission, policies and goals.

The InBC board members were selected through a comprehensive process, guided by the principles of the Crown Agencies and Board Resourcing Office. Candidates with a variety of relevant backgrounds were considered to form a strong board consisting of seven women and two men. The members appointed represent diversity as well as appropriate areas of expertise.

The following people were selected as members on the board of directors:

  • Christine Bergeron, president and CEO, Vancity
  • Kevin Campbell, managing director of investment banking, board of directors, Haywood Securities
  • Ingrid Leong, VP finance for JH Investments and chief investment officer, Houssian Foundation
  • Glen Lougheed, serial tech entrepreneur and angel investor
  • Suzanne Trottier, vice-president of Indigenous trust services, First Nations Bank Trust
  • Carole James, former minister of finance and deputy premier, Government of British Columbia
  • Iglika Ivanova, senior economist, public interest researcher, BC Office of the Canadian Centre for Policy Alternatives
  • Bobbi Plecas, deputy minister, B.C.’s Ministry of Jobs, Economic Recovery and Innovation
  • Heather Wood, deputy minister, B.C.’s Ministry of Finance

Legislation to provide the governance framework for InBC was introduced by the legislative assembly on April 27, 2021.

Board experience at growing a startup?

This group of people doesn’t seem to have a shred of experience with startups. Glen Lougheed’s “serial tech entrepreneur and angel investor” description means nothing to me and the description he provides in his LinkedIn profile doesn’t clear up matters,

I am a product and business development professional with an entrepreneurial attitude and strong technical skills. I have been building companies both mine and others since I was a teenager.

Having looked up the two companies for which he is currently acting as Chief Executive Officer, Lougheed’s interest appears to be focused on the use of ‘big data’ in marketing and communications campaigns.

Perhaps startup experience isn’t necessary since the board has been appointed to do this (from the BC Ministry of Jobs, Economic Recovery and Innovation May 6, 2021 news release; click on the Backgrounder),

Responsibilities of the InBC Investment Corp. board of directors

The board of directors will be responsible for oversight of the management of the affairs of the corporation. This includes:

  • selecting and approving the chief executive officer and chief innovation officer and monitoring performance and accountabilities;
  • reviewing and approving annual corporate financial statements;
  • oversight of policies that relate to InBC’s mandate and holding the executive to account for its accountabilities with respect to InBC’s mandate;
  • oversight of InBC’s operations; and
  • selection and appointment of InBC’s auditor.

Relationships

So, we have two government civil servants, Wood (Deputy Minister of B.C.’s Ministry of Finance) and Plecas (Deputy Minister of B.C.’s Ministry of Jobs, Economic Recovery and Innovation), and James, a BC Minister of Finance, who left the job several months ago. Then we have Lougheed, recently resigned (May 2021) as special advisor on innovation and technology to the BC Minister of Jobs, Economic Recovery and Innovation.

It would seem almost half of this new board is or has been affiliated with the government and, likely, know each other.

I expect there are more relationships to be found but my interest is in the overall picture as it pertains to the biotechnology scene. This board (except possibly for Lougheed) does not seem to have any experience in the biotechnology sector or growing any sort of startup business in any technology field.

Presumably, the new chief executive officer (CEO) and new chief innovation officer (CIO) will have some of the necessary experience. Still, biotechnology isn’t the same as digital technology, an area where the BC technology community is quite strong. (The Canadian federal government’s Digital Technology Supercluster is headquartered in BC.)

I imagine the politics around who gets hired as CEO and as CIO will be quite interesting.

See the ‘Updates and extras’ at the end of this posting for more mention of this ‘secretive’ government corporation.

The BC biotech gorillas

AbCellera was BC’s biggest biotech story in 2020/21 (see my Avo Media, Science Telephone, and a Canadian COVID-19 billionaire scientist post from December 30, 2020 for more. Do check out the subsection titled “Avo Media …” for a look at an unexpectedly interlaced relationship). Note: The AbCellera COVID-19 treatment is not a vaccine or a vaccine delivery system.

It was a bit surprising that Acuitas Therapeutics didn’t get more attention although Hoekstra seems to have addressed that shortcoming in his May 7, 2021 article by using Thomas Madden and Acuitas as the hook for the story,

By early 2020, concern was mounting about a new, deadly coronavirus first detected in Wuhan, China.

The World Health Organization had declared the coronavirus outbreak a global health emergency just days before. There had been more than 400 deaths and more than 20,000 cases, most of those in China.

But the virus was spreading around the world. Deaths had occurred in Hong Kong and the Philippines, and the virus had been detected in the U.S. and Canada.

By early January of 2020, scientists in China had already sequenced the virus’s genome and made it public, allowing scientists to begin the research for a vaccine.

Scientists expected that could take years.

But, as a second case was confirmed in B.C. in early February, Thomas Madden, a world-renowned expert in nanotechnology who heads Vancouver-based biotech company Acuitas Therapeutics, flew to Germany. [emphases mine]

Acuitas was in the business of creating lipid nanoparticles, microscopic biological vehicles that could deliver drugs [emphasis mine] — for example, to specifically target cancers in the body.

Scientists are already beginning to say it’s likely that a booster vaccine will be needed [emphasis mine] next year to deal with the virus variants.

Madden, the head of Acuitas, says it makes absolute sense to use the new biotechnology, for example, the use of messenger RNA vaccines, to prepare and fight future pandemics.

Says Madden [emphasis mine]: “The technology in terms of what it’s able to do is absolutely phenomenal. It’s just taken us 40 years to get here.”

So, Hoekstra reminds us of the international nature and urgency of the crisis, then, introduces Acuitas as a vital and local player in solutions deployed internationally, and, finally, brings us back to Acuitas after providing an overview of the BC biotech scene and the federal and provincial government’s latest moves,

AbCellera Biologics is more of a supporting player, along with a number of other companies, in Hoekstra’s story,

Sandwiched in the middle, you’ll find what I think is the point of the story,

LifeSciences BC and the provincial government’s commitments

From Hoekstra’s May 7, 2021 article,

The importance of the biotech sector in providing protection against pandemics has caught the attention of the federal and B.C. governments. It has also been noticed by the private markets.

In its budget [April 19, 2021] earlier this month [sic], the federal government promised more than $2 billion in the next seven years to support “promising” life sciences and bio-manufacturing firms, research, training, education and vaccine candidates.

Some companies, including Precision NanoSystems, have already got federal funding. The Vancouver company received $18.2 million last year to help develop its self-replicating mRNA vaccine and another $25 million in early 2021 to assist building a $50-million facility to produce the vaccine.

Last fall, Symvivo received $2.8 million from the National Research Council to help develop its oral COVID-19 vaccine.

AbCellera has also received a pledge of $175.6 million to help build an accredited manufacturing facility in Vancouver [emphasis mine] to produce antibody treatments.

AbCellera expects to double its 230-person workforce over the next two years as it expands its Vancouver campus.

When AbCellera became a publicly traded company late last year, it raised more than $500 million and had a recent market capitalization, the value of its stock, of about $8.5 billion.

When the B.C. government delivered its throne speech recently, the contribution of the province’s life sciences sector in the fight against the COVID-19 pandemic was highlighted, with Precision NanoSystems, AbCellera and StarFish Medical getting mentions. “Their work will not only help bring us out of the pandemic, it will position our province for success in the years ahead,” said B.C.’s Lt. Gov. Jane Austen in delivering the throne speech.

When the budget was released the following week [April 20, 2021], B.C. Finance Minister Selina Robinson said a new three-year, $500-million strategic investment fund would help support and scale up tech firms.

Despite their successes, B.C. biotech firms have faced challenges.

SaNOtize had to go to the U.K. to get support for clinical trials and AbCellera has been disappointed that despite Health Canada emergency approval of its COVID-19 treatment, provinces have been reluctant to use Bamlanivimab.

Hansen, AbCellera’s CEO and a former University of B.C. professor with a PhD in applied physics and biotechnology, said he believes that biotech is the most important frontier of technology.

In the past, while great science was launched from B.C.’s universities, not as great a job was done on turning that science into innovation, jobs [emphasis mine] and the capacity to bring new products to market, possibly because of a lack of entrepreneurship and polices to make it more attractive to companies to grow and thrive here and move here, notes Hansen.

Hurlburt [Wendy Hurlburt], the LifeSciences B.C. CEO, says that policies, including tax structure and patenting [emphasis mine], that encourages innovation companies are needed to support the biotech sector.

But, adds Hansen: “Here in Vancouver, I feel like we’re turning the corner. There’s probably never been a time when Vancouver’s biotech sector [emphasis mine] was stronger. And the future looks very good.”

Not only is the province involved but so is the City of Vancouver (more about that in a bit).

It’s not all about the cash

Hoekstra’s May 7, 2021 article helped answer a question I had in the title of another posting, January 22, 2021: Why is Precision Nanosystems Inc. in the local (Vancouver, Canada) newspaper? (See the ‘Updates and extras’ at the end of this posting for more to the answer.)

This campaign has been building for a while. In the “Is it magic or how does the federal budget get developed? subsection of my May 4, 2021 posting on the 2021 Canadian federal budget I speculated a little bit,

I believe most of the priorities are set by power players behind the scenes. We glimpsed some of the dynamics courtesy of the WE Charity scandal 2020/21 and the SNC-Lavalin scandal in 2019.

Access to special meetings and encounters are not likely to be given to any member of the ‘great unwashed’ but we do get to see the briefs that are submitted in anticipation of a new budget. These briefs and meetings with witnesses are available on the Parliament of Canada website (Standing Committee on Finance (FINA) webpage for pre-budget consultations.

AbCellera submitted a brief dated August 7, 2020 (PDF) detailing how they would like to see the Income Tax Act amended. It’s not always about getting cash, although that’s very important. In this brief, the company wants “… improved access to the enhanced Scientific Research & Experimental Development tax credit.”

There are many aspects to these campaigns including the federal Income Tax Act and, in this case, municipal involvement.

Vancouver (city government) and the biotech sector

About five weeks prior to the 2021 Canadian federal budget and BC provincial budget announcements, there was some news from the City of Vancouver (from a March 10, 2021 article by Kenneth Chan for dailyhive.com), Note: Links have been removed,

Major expansion plans are abound for AbCellera over the next few years to the extent that the Vancouver-based biotechnology company is now looking to build a massive purpose-built office and medical laboratory campus in Mount Pleasant (Vancouver neighbourhood).

It would be a redevelopment of the entire city block …

… earlier today, Vancouver City Council unanimously approved a rezoning enquiry allowing city staff to work with the proponent and accept a formal application for review.

This special additional pre-application step is required due to the temporary ban [emphasis mine] on most types of rezonings within the Broadway Plan’s planning area, until the plan is finalized at the end of 2021.

But city staff are willing to make this a rare exception due to the economic opportunity [emphasis mine] presented by the proposal and the healthcare-related aspects.

“The reasons for advancing this quickly are they are rapidly growing and would like to stay in Vancouver, and we would like them to… We’re very glad to have this company in Vancouver and want to provide them with a permanent home, but in order to scale up, the timeframe to produce their therapy [for viruses] is really time sensitive,” Gil Kelley, the chief urban planner of the City of Vancouver, told city council during today’s [March 10, 2021] meeting.

….

Roughly 10 days after the 2021 budgets are announced, there’s this from Kenneth Chan’s April 29,2021 article on dailyhive.com,

Plans for AbCellera Biologics’ major footprint expansion in Vancouver’s Mount Pleasant Industrial Area are moving forward quickly.

Based on the application submitted this week, the Vancouver-based biotechnology company is proposing to redevelop 110 West 4th Avenue …

It will be designated as the rapidly growing company’s global headquarters.

… city staff are providing AbCellera with the highly rare, expedited stream of combining the rezoning and development application processes into one.

By the middle of this decade, AbCellera will have four locations in the area, including its current 21,000 sq ft office at 2215 Yukon Street and a new 44,000 sq ft office nearing completion at 2131 Manitoba Street, just south of its future main hub.

“We’re building state-of-the-art facilities in Vancouver to accelerate the development of new antibody therapies with biotech and pharma partners from around the world,” said Carl Hansen, CEO and president of AbCellera, in a statement.

AbCellera has gained significant international attention over the past year after it co-developed the first authorized COVID-19 antibody therapy for emergency use in high-risk patients in Canada and the United States.

In late 2020, the company closed a successful initial public offering, bringing in $556 million after selling nearly 28 million shares, far exceeding its original goal of raising $250 million. It was the largest-ever IPO [initial public offering] by a Canadian biotech company.

“We see this new site as a creative hub for engineers, software developers, data scientists, biologists and bioinformaticians to collaborate, innovate, and push the frontiers of technology.” [said Veronique Lecault, the COO of AbCellera]

Additionally, AbCellera is also planning to build a clinical-grade, antibody manufacturing facility in Metro Vancouver, funded in part by the $176-million investment it received from the federal government in Spring 2020 [see May 3, 2020 AbCellera news release].

Not cash but AbCellera did get an expedited process for rezoning and I imagine there will be more special treatment as this progresses. (See the ‘Updates and extras’ at the end of this posting for news about the expedited process.)

It’s likely there are other companies in the BC’s life science sector that are eyeing this development with great interest and high hopes for themselves.

What it takes

COVID-19 seems to have galvanized interest and support almost everywhere in the world for life sciences.

I don’t believe that anyone in the life sciences planned for or rejoiced at news of this pandemic. However, the Canadian biotech sector has been working for decades to establish itself as an important economic resource. and, sadly, COVID-19 has been a timely development.

All those years of lobbying, also known as, government relations, marketing, investor relations, public relations and more served as preparation for what looks like a concerted effort and it has paid off in BC at the federal level, provincial level, and municipal level (at least one).

The campaigns continue. Here’s Wendy Hurlburt, president and CEO of LifeSciences BC in a May 14, 2021 Conversations That Matter Vancouver Sun podcast with Stuart McNish. Note: Hurlburt makes an odd comment at about the 7 min. 30 secs. mark regarding insulin and patents.

Her dismay over lost opportunities regarding the insulin patent is right in line with Canada’s current patent mania. See my May 13, 2021 posting, Not a pretty picture: Canada and a patent rights waiver for COVID-19 vaccines. As far as I’m aware, Canada’s stance has not changed. Interestingly, Hoekstra’s article doesn’t mention COVID-19 patent waivers.

By contrast, here’s what Frederick Banting (one of the discoverers) had to say about his patent, (from the Banting House Insulin Patents webpage),

About the sale of the patent of insulin for $1 Banting reportedly said, “Insulin belongs to the world, not to me.”

… On January 23rd, 1923 Banting, [Charles] Best, and [James] Collip were awarded the American patents for insulin which they sold to the University of Toronto for $1.00 each.

Hurlburt goes on to express dismay over taxes and notes that some companies may leave for other jurisdictions, which means we will lose ‘innovation’. This is a very common ploy coming from any of the technology sectors and can be dated back at least 30 years.

Unmentioned is the dream/business model that so many Canadian tech entrepreneurs have: grow the company, sell it for a lot of money, and retire, preferably before the age of 40.

Getting back to my point, the current situation is not attributable to one individual or to one company’s efforts or to one life science nonprofit or to one federal Network Centre for Excellence (NanoMedicines Innovation Network [NMIN] located at the University of British Columbia).

Note: I have more about the NMIN and Acuitas Therapeutics in a November 12, 2021 posting and there’s more about NMIN’s 7th annual conference and a very high profile guest in a September 11, 2020 posting.

Strategy at the federal, provincial, and local governments, with an eye to the international scene, has been augmented by luck and opportunism.

Updates and extras

Where updates are concerned I have one for Precision Nanosystems and one for AbCellera. I have extras with regard to Moderna and Canada and, BC’s special fund, inBC Investment Corporation. For anyone who’s curious about Banting and the high cost of insulin, I have a couple of links to further reading.

Precision Nanosystems

From an August 11, 2021 article by Kenneth Chan (Note: Links have been removed),

A homegrown pharmaceutical company has announced plans to significantly scale its operations with the opening of a new production facility in Vancouver’s False Creek Flats.

The new Evolution Block building will contain PNI’s new global headquarters and a new genetic medicine Good Manufacturing Practice (GMP) biomanufacturing centre, which would allow the company to expand its capabilities to include the clinical manufacturing of RNA vaccines and therapeutics.

Federal funding totalling $25.1 million for PNI was first announced in February 2021 towards covering part of the development costs of such a facility, as part of the federal government’s new strategy to better ensure Canada has the domestic capacity to secure its own COVID-19 vaccines and prepare the country for future pandemics. It is estimated the vaccine production capacity of the new facility will be 240 million doses annually.

PNI’s location in the False Creek Flats is strategic, given the close proximity to the new St. Paul’s Hospital campus and the growing concentration of tech and healthcare-based industrial businesses.

AbCellera

From a June 22, 2021 article by Kenneth Chan (Note: Links have been removed),

The rapidly growing Vancouver-based biotechnology company announced this morning their 130,000 sq ft Good Manufacturing Practices (GMP) facility will be located on a two-acre site at the 900 block of Evans Avenue, replacing the Urban Beach volleyball courts just next to the City of Vancouver’s Evans maintenance centre and the Regional Recycling Vancouver Bottle Depot.

GMP is partially funded by the $175 million in federal funding received by the company last year to support research into coronavirus treatment.

GMP adds to AbCellera’s major plans to build a new headquarters in close proximity at 110-150 West 4th Avenue in the Mount Pleasant Industrial Area — a city block-sized campus with a total of 380,000 sq ft of laboratory and office space for research and corporate uses.

Both campus buildings are being reviewed under the City of Vancouver’s rare streamlined, expedited process [emphasis mine] of combining the rezoning and development permit applications. AbCellera formally announced its campus plans in April 2021.

AbCellera gained significant international attention last year when it developed the world’s first monoclonal antibody therapy for COVID-19 to be authorized for emergency use in high-risk patients in Canada and the United States. According to the company, over 400,000 doses of its bamlanivimab drug have been administered around the world, and it is estimated to have kept more than 22,000 people out of hospital — saving at least 11,000 lives.

In late 2020, the company closed a successful initial public offering, bringing in $556 million after selling nearly 28 million shares, far exceeding its original goal of raising $250 million. It was the largest-ever IPO by a Canadian biotech company.

Moderna and Canada

It seems like yesterday that Derek Rossi (co-founder of Moderna) was talking about Canada’s need for a biotechnology hub. (see this June 17, 2021 article by Barbara Shecter for the Financial Post). Interestingly, there’s been an announcement of a memorandum of understanding (these things are announced all the time and don’t necessarily result in anything) between Moderna and the government of Canada according to an August 10, 2021 item on the Canadian Broadcasting Corporation (CBC) news website,

Massachusetts-based drug maker Moderna will build an mRNA vaccine manufacturing plant in Canada within the next two years, CEO Stephane Bancel said Tuesday [August 10, 2021; Note the timing, the writ for the next federal election was dropped on August 15, 2021].

The company has signed a memorandum of understanding with the federal government that will result in Canada becoming the home of Moderna’s first foreign operation. It’s not clear yet how much money Canada has offered to Moderna [emphasis mine] for the project.

Canada, whose life sciences industry has been decimated over the last three decades, wants in on the action. Prime Minister Justin Trudeau has promised to rebuild the industry, and the recent budget included a $2.2 billion, seven-year investment to grow the life science and biotech sectors.

Almost half of that targets companies that want to expand or set up vaccine and drug production in Canada. None of the COVID-19 vaccines to date have been made in Canada, leaving the country entirely reliant on imports to fill vaccine orders. As a result, Canada was slower out of the gate on immunizations than some of its counterparts with domestic production, and likely had to pay more per dose for some vaccines as well.

The location of the new facility hasn’t been finalized, but Bancel said the availability of an educated workforce will be the main deciding factor. He said the design is done and they’ll need to start hiring very soon so training can begin.

it’s not exactly a hub but who knows what the future will bring? I imagine there’s going to be some serious wrangling behind the scenes as the provinces battle to be the location for the facility. Note that Innovation Minister François-Philippe Champagne who made the announcement with Bancel in Montréal represents a federal riding in Québec. (BTW, Bancel is from France and seems to have spent much of his adult life in the US.) Of course anything can happen and I’m sure the BC contingent will make themselves felt but it would seem that Quebec is the front runner for now, assuming this memorandum of understanding leads to a facility. Given that we are in the midst of a federal election, it seems more probable than it might otherwise.

inBC Investment Corporation

Bob Mackin’s August 13, 2021 article for theBreaker.news sheds some light on how that corporation was formed so very quickly and more,

The B.C. NDP government rejigged the B.C. Immigrant Investor Fund last year, but refused to release the business case when it was rebranded as inBC Investment Corp. in late April [2021].

theBreaker.news requested the business case for the $500 million fund, which is overseen by a board of NDP patronage appointees, on May 6 [2021].

The 123-page document below is heavily censored — meaning the NDP cabinet is refusing to tell British Columbians the projected operating costs (including board expenses, salary and benefits, office space, operating and administration), full-time equivalents, and cash flows for the newest Crown corporation. inBC bills itself as a triple-bottom line organization, meaning it intends to invest on the basis of social, environmental and economic values.

When its enabling legislation was tabled, the NDP took steps to exempt inBC from the freedom of information law.

Thank you, Mr. Mackin.

More on Banting, insulin and patents

Caitlyn McClure’s 2016 article (Insulin’s Inventor Sold the Patent for $1. Then Drug Companies Got Hold of It.) for other98.com is a brief and pithy explanation for why insulin costs so much. Alanna Mitchell’s August 13, 2019 article for Maclean’s magazine investigates ‘insulin tourism’ and offers more detail as to how this situation has come about.

One last reminder, my August 20, 2021 posting (Getting erased from the mRNA/COVID-19 story) about Ian MacLachlan provides insight into how competitive and rough the bitotechnology scene can be here in BC/Canada.

Getting erased from the mRNA/COVID-19 story

Nathan Vardi’s August 17, 2021 article for Forbes magazine about Ian MacLachlan and the delivery system for mRNA vaccines tells a type of story I’ve more often seen in history books. It is reminiscent of the Thomas Edison and Nikola Tesla story of electricity. One gets all the glory while the other is largely forgotten.

I’m especially interested as much of this concerns players in the local (Vancouver, British Columbia, Canada) biotechnology scene. Vardi’s August 17, 2021 article sets the scene,

“The whole mRNA platform is not how to build an mRNA molecule; that’s the easy thing,” Bourla [Pfizer CEO Albert Bourla] says. “It is how to make sure the mRNA molecule will go into your cells and give the instructions.” 

Yet the story of how Moderna, BioNTech and Pfizer managed to create that vital delivery system has never been told. It’s a complicated saga involving 15 years of legal battles and accusations of betrayal and deceit. [emphases mine] What is clear is that when humanity needed a way to deliver mRNA to human cells to arrest the pandemic, there was only one reliable method available—and it wasn’t one originated in-house by Pfizer, Moderna, BioNTech or any of the other major vaccine companies. 

A months-long investigation by Forbes reveals that the scientist most responsible for this critical delivery method is a little-known 57-year-old Canadian biochemist named Ian MacLachlan. As chief scientific officer of two small companies, Protiva Biotherapeutics and Tekmira Pharmaceuticals, MacLachlan led the team that developed this crucial technology. Today, though, few people—and none of the big pharmaceutical companies—openly acknowledge his groundbreaking work, and MacLachlan earns nothing from the technology he pioneered. 

I have three stories (on this blog) mentioning Tekmira (all from 2014 or 2015) and none mentioning Protiva nor, for that matter, Ian MacLachlan.

Back to Vardi’s August 17, 2021 article,

Moderna Therapeutics vigorously disputes the idea that its mRNA vaccine uses MacLachlan’s delivery system, and BioNTech, the vaccine maker partnered with Pfizer, talks about it carefully. Legal proceedings are pending, and big money is at stake. 

Moderna, BioNTech and Pfizer are on their way to selling $45 billion worth of vaccines in 2021. They don’t pay a dime to MacLachlan. Other coronavirus vaccine makers, such as Gritstone Oncology, have recently licensed MacLachlan’s Protiva-Tekmira delivery technology for between 5% and 15% of product sales. MacLachlan no longer has a financial stake in the technology, but a similar royalty on the Moderna and Pfizer-BioNTech vaccines could yield as much as $6.75 billion in 2021 alone. …

Vardi provides evidence (Note: A link has been removed from the August 17, 2021 article excerpt,

Despite their denials, scientific papers and regulatory documents filed with the FDA [US Food and Drug Administration] show that both Moderna and Pfizer-BioNTech’s vaccines use a delivery system strikingly similar to what MacLachlan and his team created—a carefully formulated four-lipid component that encapsulates mRNA in a dense particle through a mixing process involving ethanol and a T-connector apparatus. 

For years, Moderna claimed it was using its own proprietary delivery system, but when it came time for the company to test its Covid-19 vaccine in mice, it used the same four kinds of lipids as MacLachlan’s technology, in identical ratios. 

According to Vardi’s LinkedIn profile: “I am a senior editor at Forbes, where I am responsible for the coverage of hedge funds, private equity, and other big investors. I lead investigative reporting efforts and have written 20 cover stories for Forbes Magazine,” he does not appear to have any medical or bioscience expertise (Bachelor of Journalism from Carleton University [Canada] and Masters of International Affairs from Columbia University [US].) Presumably someone he consulted or someone on his team provided the skills necessary for analyzing the scientific papers and documents.

You may recognize this scientist (from the August 17, 2021 article),

Not everyone ignores MacLachlan. “A lot of credit goes to Ian MacLachlan for the LNP [lipid nanoparticle],” says Katalin Karikó, [emphasis mine] the scientist who laid the groundwork for mRNA therapies before joining BioNTech in 2013. But Karikó, now a frontrunner for a Nobel Prize, is angry that MacLachlan didn’t do more to help her use his delivery system to build her own mRNA company years ago. “[MacLachlan] might be a great scientist, but he lacked vision,” she says.

I have more about Karikó and her role in the mRNA vaccine story here in a March 5, 2021 posting.

As for MacLachlan’s start (from the August 17, 2021 article),

… With a Ph.D. in biochemistry, MacLachlan joined Inex in 1996, his first job after completing a postdoctoral fellowship in a gene lab at the University of Michigan. 

Inex was cofounded by its chief scientific officer, Pieter Cullis, now 75, a long-haired physicist who taught at the University of British Columbia. From his perch there Cullis started several biotechs, cultivating an elite community of scientists that made Vancouver a hotbed of lipid chemistry. 

As companies rise and fall with intellectual property being assigned to one company or other, legal brawls ensue. This was the time that Karikó came knocking on the door, from the August 17, 2021 article,

It was in the midst of all this furious legal fighting that Hungarian biochemist Katalin Karikó first showed up at MacLachlan’s door. Karikó was early to grasp that MacLachlan’s delivery system held the key to unlocking the potential of mRNA therapies. As early as 2006, she began sending letters to MacLachlan urging him to encase her groundbreaking chemically altered mRNA in his four-lipid delivery system. Embroiled in litigation, MacLachlan passed on her offer. 

Karikó didn’t give up easily. In 2013, she flew to meet with Tekmira’s executives, offering to relocate to Vancouver and work directly under MacLachlan. Tekmira passed. “Moderna, BioNTech and CureVac all wanted me to work for them, but my number one choice, Tekmira, didn’t,” says Karikó, who took a job at BioNTech in 2013. 

By this time, Moderna CEO Stéphane Bancel [emphasis mine] was also trying to solve the delivery puzzle. Bancel held discussions with Tekmira about collaborating, but talks stalled. At one point, Tekmira indicated it wanted at least $100 million up front, plus royalties, to strike a deal.

Instead, Moderna partnered with Madden [Thomas Madden], who was still working with Cullis at their drug delivery company, Acuitas Therapeutics.  …

I have been wondering why Acuitas Therapeutics hasn’t been getting all that much attention in the hyperbolic discussions about British Columbia’s (or Vancouver’s) thriving biotechnology scene. (I’ll have more about the ‘scene’ in a later posting.) Perhaps all this legal wrangling is not considered helpful when bragging. (I do have a November 12, 2020 post, which features Acuitas, an interview with its president and chief executive office Dr. Thomas Madden, and an explanation of their technology.)

As for Moderna, I have a special interest as the company has announced plans to open a production facility here in Canada and one of Moderna’s founders is Canadian, Derek Rossi. (He too is mentioned in the March 5, 2021 posting, scroll down to the ‘Entrepreneurs rush in’ subhead; he is not an altogether happy camper.)

Rossi has opinions on how we should be doing things here as noted in a June 17, 2021 article by Barbara Shecter for the Financial Post (Moderna founder says Canada needs to build a biotech hub to avoid ‘getting caught with its pants down next time’). Thank you, Mr. Rossi. (I’m more familiar with clusters than hubs [hubs were a popular topic of conversation about 20 years ago but in Canada we seem more interested in clusters; see John Newbigin’s “Hubs, clusters and regions” on britishcouncil.org for a description of the differences].)

As for Moderna’s response to all of the legal wrangling over mRNA delivery systems, from Vardi’s August 17, 2021 article,

Moderna pursued a different strategy. It filed lawsuits with the U.S. Patent and Trademark Office seeking to nullify a series of patents related to MacLachlan’s delivery system, now controlled by Genevant. But in July 2020, as Moderna was pushing its vaccine through clinical trials, an adjudicative body largely upheld the most important patent claims. (Moderna is appealing.)

I highly recommend reading Vardi’s August 17, 2021 article as I have not done justice to all of the ‘ins and outs’ of the story.

You can see how thoroughly MacLachlan has been erased form the lipid nanoparticle delivery system/COVID-19 vaccine story in this May 24 ,2021 posting (Lipid nanoparticles: The underrated invention behind the vaccine revolution) by Nada Salem at the Science Borealis blog. It is largely a description of the technology and in the last two paragraphs a history of its development with no mention of MacLachlan or any of his companies.

One last thought, I wonder how Vardi found out about MacLachlan. Could someone have brought the story to his attention and who might that have been?

Litus, a University of Calgary spin-off company, and its lithium extraction process

This company is very secretive. Other than some information about the technology everything else is a mystery. From an April 28, 2021 news item on mining.com,

Litus announced the launching of LiNC, a patent-pending lithium extraction solution initially developed at the University of Calgary in Alberta, Canada.

In a press release, the company said that the nanotechnology composite material within LiNC has very strong ionic affinity and lithium selectivity in the presence of high concentrations of competing ions such as sodium, magnesium and calcium. 

According to Litus, its technology is able to efficiently and sustainably extract more lithium from brine sources than similar methods.

“Demand for lithium is growing at a rate that current production methods and technologies simply can’t meet. Through the application of LiNC, mining companies have an opportunity to not only increase the reserves and production of their existing assets but should be able to open up new sources of lithium that have been either uneconomic or too environmentally sensitive to be practical with previous extraction technology,” the firm’s statement reads.

There is another company which also extracts lithium from the brine in oil wells; their claim to fame is a ‘greener’ extraction method (see my February 23, 2021 posting about Summit Nanotech, which is also located in Calgary, Alberta.)

Getting back to the mysterious Litus,I found this on the About Us section of their homepage,

The Company was formed in 2019 on research originally conducted at the University of Calgary. 

Litus is passionate about developing and supporting technology products that inspire its customers and partners to create energy solutions that are more abundant, more accessible, cleaner, safer, and more efficient. 

The Company is currently applying its leadership in nanotechnology and chemical processing to help companies produce lithium more efficiently and cleanly than previously possible.

THE TEAM

Litus is led by an exceptional group of professional chemists, nanotechnologists, and chemical process engineers, as well as experienced entrepreneurial business professionals. The team has a proven track record of success with both scientific achievements, and in scaling new technologies to become industrially and commercially successful solutions.

You can check out the company’s LinkedIn profile but it’s not particularly useful. There are apparently nine employees but none are identified and the description of the company’s technology is the same as what can be found on their website’s homepage.

Should you be interested in the ‘lithium extraction from brine’ industry, Gabriel Friedman’s February 9, 2021 article for the Financial Post provides some insight into the competitiveness and volatility of this still niche market.

New water treatment with 3D-printed graphene aerogels

Caption: Graphene aerogel on a single tissue. Credit: University at Buffalo

That image of the graphene aerogel on a tissue shows off its weightlessness very well.

Here’s more about the graphene aerogel water treatment from an April 14, 2021 news item on Nanowerk,

Graphene excels at removing contaminants from water, but it’s not yet a commercially viable use of the wonder material.

That could be changing.

In a recent study, University at Buffalo [UB] engineers report a new process of 3D printing graphene aerogels that they say overcomes two key hurdles — scalability and creating a version of the material that’s stable enough for repeated use — for water treatment.

“The goal is to safely remove contaminants from water without releasing any problematic chemical residue,” says study co-author Nirupam Aich, PhD, assistant professor of environmental engineering at the UB School of Engineering and Applied Sciences. “The aerogels we’ve created hold their structure when put in water treatment systems, and they can be applied in diverse water treatment applications.”

An April 14, 2021 UB news release (also on EurekAlert) by Melvin Bankhead III, which originated the news item, explains the breakthrough in more detail,

An aerogel is a light, highly porous solid formed by replacement of liquid in a gel with a gas so that the resulting solid is the same size as the original. They are similar in structural configuration to Styrofoam: very porous and lightweight, yet strong and resilient.

Graphene is a nanomaterial formed by elemental carbon and is composed of a single flat sheet of carbon atoms arranged in a repeating hexagonal lattice.

To create the right consistency of the graphene-based ink, the researchers looked to nature. They added to it two bio-inspired polymers — polydopamine (a synthetic material, often referred to as PDA, that is similar to the adhesive secretions of mussels), and bovine serum albumin (a protein derived from cows).

In tests, the reconfigured aerogel removed certain heavy metals, such as lead and chromium, that plague drinking water systems nationwide. It also removed organic dyes, such as cationic methylene blue and anionic Evans blue, as well as organic solvents like hexane, heptane and toluene.

To demonstrate the aerogel’s reuse potential, the researchers ran organic solvents through it 10 times. Each time, it removed 100% of the solvents. The researchers also reported the aerogel’s ability to capture methylene blue decreased by 2-20% after the third cycle.

The aerogels can also be scaled up in size, Aich says, because unlike nanosheets, aerogels can be printed in larger sizes. This eliminates a previous problem inherent in large-scale production, and makes the process available for use in large facilities, such as in wastewater treatment plants, he says. He adds the aerogels can be removed from water and reused in other locations, and that they don’t leave any kind of residue in the water.

Aich is part of a collaboration between UB and the University of Pittsburgh, led by UB chemistry professor Diana Aga, PhD, to find methods and tools to degrade per- and polyfluoroalkyl substances (PFAS), toxic materials so difficult to break down that they are known as “forever chemicals.” Aich notes the similarities to his work with 3D aerogels, and he hopes results from the two projects can be brought together to create more effective methods of removing waterborne contaminants.

“We can use these aerogels not only to contain graphene particles but also nanometal particles which can act as catalysts,” Aich says. “The future goal is to have nanometal particles embedded in the walls and the surface of these aerogels and they would be able to degrade or destroy not only biological contaminants, but also chemical contaminants.”

Aich, Chi, and Masud [Arvid Masud, PhD] hold a pending patent for the graphene aerogel described in the study, and they are looking for industrial partners to commercialize this process.

Here’s link to and a citation for the paper,

Emerging investigator series: 3D printed graphene-biopolymer aerogels for water contaminant removal: a proof of concept by Arvid Masud, Chi Zhoub and Nirupam Aich. Environ. Sci.: Nano, 2021,8, 399-414 DOI: https://doi.org/10.1039/D0EN00953A First published online: 09 Dec 2020

This paper is behind a paywall.

A Science Fiction/Real Policy Book Club on June 9, 2021

The link between science fiction and science innovation and technology has been documented and argued over elsewhere online and in print. However, the link between policy and science fiction is new to me.

First, here’s the upcoming event which caught my eye (from the Science Fiction/Real Policy Book Club event page),

[ONLINE] – Science Fiction/Real Policy Book Club: Autonomous by Annalee Newitz

Science fiction can have real science policy impacts, and comes rife with real-life commentary. And with such a rich cache of science fiction to choose from, we think a book club is in order.

Join us [emphasis mine] for the first installment of our Science Fiction/Real Policy book club, a partnership with Issues in Science and Technology. Our first read will be Autonomous by Annalee Newitz. Autonomous follows the story of a female pharmaceutical pirate named Jack, an anti-patent scientist who has set out to bring cheap drugs to the poor. Without giving away too many spoilers, Newitz’s tale also includes a military agent-robot love story, a quest for justice, and the danger late capitalist modernity poses to personhood.

Join us for a jam-packed evening where we’ll discuss Autonomous and the questions it raises about labor and power, robot ethics, gender, patent law, the pharmaceutical industry, geopolitics, and much more.

Featured discussants

Joey Eschrich
Editor and Manager, Center for Science and the Imagination at Arizona State University [ASU]

Tahir Amin
Co-Founder and Co-Executive Director, I-MAK

When

Jun. 9, 2021 [Wednesday]
6:00 pm – 7:00 pm

Where

Online Only Webcast link

RSVP here

Follow the conversation online using #FTBookClub and by following @FutureTenseNow.

Who is ‘us’?

The hosting organization is New America (newamerica.org). If you click on their About tab/button, you’ll find this,

We are dedicated to renewing the promise of America by continuing the quest to realize our nation’s highest ideals, honestly confronting the challenges caused by rapid technological and social change, and seizing the opportunities those changes create.

Amongst other programs, New America is participating in Future Tense,

Future Tense is a partnership between New America, Arizona State University, and Slate magazine to explore emerging technologies and their transformative effects on society and public policy. Central to the partnership is a series of events that take in-depth, provocative looks at issues that, while little-understood today, will dramatically reshape the policy debates of the coming decade.

It took me a while but I finally realized that the book club is a Future Tense initiative.

As for I-MAK, it’s an organization devoted to improving access to medicines globally and amongst other activities, solving the drug patent problem.

Not a pretty picture: Canada and a patent rights waiver for COVID-19 vaccines

At about 7:15 am PT this morning , May 13, 2021, I saw Dr. Mona Nemer’s (Canada’s Chief Science Advisor) tweet (Note: I’m sorry the formatting isn’t better,

Maryse de la Giroday@frogheart Does this mean Canada will support a waiver on patent rights for COVID-19 vaccines?

7:18 AM · May 13, 2021

Dr. Mona Nemer@ChiefSciCanThe global health crisis of the past year has underscored the critical importance of openly sharing scientific information. We are one step closer to making #openscience a reality around the world. So pleased that my office was part of these discussions. http://webcast.unesco.org/events/2021-05-OS-IGM/ Quote Tweet

Canada at UNESCO@Canada2UNESCO · May 6@Canada2UNESCO is partaking in negotiations today on the draft recommendation on #OpenScience The benefits of #science and #technology to health, the #economy and #development should be available to all.6:40 AM · May 13, 2021·Twitter Web App

No reply. No surprise

Brief summary of Canada’s COVID-19 patent rights nonwaiver

You’ll find more about the UNESCO meeting on open science in last week’s May 7, 2021 posting (Listen in on a UNESCO (United Nations Educational, Scientific and Cultural Organization) meeting [about Open Science]).

At the time, I noted a disparity in Canada’s policies centering on open science and patents; scroll down to the “Comments on open science and intellectual property in Canada” subsection for a more nuanced analysis. For those who don’t have the patience and/or the time, it boils down to this:

  1. Canada is happily participating in a UNESCO meeting on open science,
  2. the 2021 Canadian federal budget just dedicated a big chunk of money to augmenting Canada’s national patent strategy, and
  3. Canada is “willing to discuss” a waiver at the World Trade Organization (WTO) meetings.

I predicted UNESCO would see our representative’s enthusiastic participation while our representative at the WTO meeting would dance around the topic without committing. to anything. Sadly, it’s starting to look like I was right.

Leigh Beadon in a May 12, 2021 posting on Techdirt reveals the situation is worse than I thought (Note: Links have been removed),

Few things illustrate the broken state of our global intellectual property system better than the fact that, well over a year into this devastating pandemic and in the face of a strong IP waiver push by some of the hardest hit countries, patents are still holding back the production of life-saving vaccines. And of all the countries opposing a waiver at the WTO (or withholding support for it, which is functionally the same thing), Canada might be the most frustrating [emphasis mine].

Canada is the biggest hoarder [emphasis mine] of vaccine pre-orders, having secured enough to vaccinate the population five times over. Despite this, it has constantly run into supply problems and lagged behind comparable countries when it comes to administering the vaccines on a per capita basis. In response to criticism of its hoarding, the government continues to focus on its plans to donate all surplus doses to the COVAX vaccine sharing program — but these promises were somewhat more convincing before Canada became the only G7 country to withdraw doses from COVAX. Despite all this, and despite pressure from experts who explain how vaccine hoarding will prolong the pandemic for everyone, the country has continually refused to voice its support for a TRIPS patent waiver at the WTO.

Momentum for changing Canada’s position on a COVID-19 vaccine patent right waivers?

Maclean’s magazine has a May 10, 2021 open letter to Prime Minister Justin Trudeau,

Dear Prime Minister Trudeau,

The only way to combat this pandemic successfully is through a massive global vaccination campaign on a scale and timeline never before undertaken. This requires the production of effective tools and technologies to fight COVID-19 at scale and coordinated global distribution efforts.

The Trade-Related Aspect of Intellectual Property Rights (TRIPS) agreement at the World Trade Organization (WTO) is leading to the opposite outcome. Vaccine production is hindered by granting pharmaceutical companies monopoly power through protection of intellectual property rights, industrial designs and trade secrets. Pharmaceutical companies’ refusal to engage in health technology knowledge transfer makes large-scale, global vaccine production in (and for) low- and middle-income countries all but impossible. The current distribution of vaccines globally speaks to these obstacles.

Hundreds of civil society groups, the World Health Organization (WHO), and the elected governments of over 100 countries, including India, Afghanistan, Bangladesh, Nepal, Pakistan and Sri Lanka have come together and stated that current intellectual property protections reduce the availability of vaccines for protecting their people. On May 5, 2021 the United States also announced its intention to support a temporary waiver for vaccines at the WTO.

We are writing to ask our Canadian government to demonstrate its commitment to an equitable global pandemic response by supporting a temporary waiver of the TRIPS agreement. But clearly that is a necessary but not a sufficient first step. We recognize that scaling up vaccine production requires more than just a waiver of intellectual property rights, so we further request that our government support the WHO’s COVID-19 Technology Access Pool (C-TAP) to facilitate knowledge sharing and work with the WTO to address the supply chain and export constraints currently impeding vaccine production. Finally, because vaccines must be rolled out as part of an integrated strategy to end the acute phase of the epidemic, we request that Canada support the full scope of the TRIPS waiver, which extends to all essential COVID-19 products and technologies, including vaccines, diagnostics and therapeutics.

The status quo is clearly not working fast enough to end the acute phase of the pandemic globally. This waiver respects global intellectual property frameworks and takes advantage of existing provisions for exceptions during emergencies, as enshrined in the TRIPS agreement. Empowering countries to take measures to protect their own people is fundamental to bringing this pandemic to an end.

Anand Giridharadas (author of the 2018 book, Winners Take All: The Elite Charade of Changing the World) also makes the case for a patent rights waiver in his May 11, 2021 posting on The Ink, Note: A link has been removed,

Patents are temporary monopolies granted to inventors, to reward invention and thus encourage more of it. But what happens when you invent a drug that people around the world require to stay alive? What happens when, furthermore, that drug was built in part on technology the public paid for? Are there limits to intellectual property?

For years, activists have pressured the United States government to break or suspend patents in particular cases, as with HIV/Aids. They have had little luck. Indeed, the United States has often fought developing countries when they try to break patents to do right by their citizens, choosing American drug companies over dying people.

So it was a dramatic swerve when, last week, the Biden administration announced that it supported a waiver of the patents for Covid vaccines.

Not long afterward, I reached out to several leading activists for vaccine access to understand the significance of the announcement and where we go from here.

in all this talk about patents and social justice and, whether it’s directly referenced or not, money, the only numbers of I’ve seen,until recently, have been numbers of doses and aggregate costs.

How much does a single vaccine dose cost?

A Sunday, April 11, 2021 article by Krassen Nikolov for EURACTIV provides an answer about the cost in one region, the European Union,

“Pfizer cost €12, then €15.50. The Commission now signs contracts for €19,50”, Bulgarian Prime Minister Boyko Borissov revealed on Sunday [April 11, 2021].

The European Commission is in talks with Pfizer for the supply of COVID-19 vaccines in 2022 and 2023. Borissov said the contracts provide for €19.50 per dose.

Under an agreement with the vaccine producing companies, the European Commission has so far refused to reveal the price of vaccines. However, last December Belgian Secretary of State Eva De Bleeker shared on Twitter the vaccine prices negotiated by the Commission, as well as the number of doses purchased by her government. Then, it became known that the AstraZeneca jab costs €1.78 compared to €12 for Pfizer-BioNTech.

€12 to €19,50, that’s an increase of over 50%. I wonder how Pfizer is justifying such a hefty increase?

According to a March 16, 2021 article by Swikar Oli for the National Post (a Canadian newspaper), these prices are a cheap pandemic special prices,

A top Pfizer executive told shareholders the company is looking at a “significant opportunity” to raise the price of its Pfizer-BioNTech COVID-19 vaccine.

While addressing investors at the virtual Barclays Global Healthcare Conference last week, Pfizer CFO Frank D’Amelio noted they could raise prices when the virus becomes endemic, meaning it’s regularly found in clusters around the globe, according to a transcript of the conference posted on Pfizer’s website.

Current vaccine pricing models are pandemic-related, D’Amelio explained. After the pandemic is defeated and “normal market conditions” arrive, he noted the window would open for a “significant opportunity…from a pricing perspective.”

“So the one price that we published is the price with the U.S. of $19.50 per dose. Obviously, that’s not a normal price like we typically get for a vaccine, $150, $175 [emphasis mine] per dose,” he said, “So pandemic pricing.”

If I remember it rightly, as you increase production, you lower costs per unit. In other words, it’s cheaper to produce one dozen than one, which is why your bakery charges you less money per bun or cake if you purchase by the dozen.

During this pandemic, Pfizer has been producing huge amounts of vaccine, which they would not expect to do should the disease become endemic. As Pfizer has increased production, I would think the price should be dropping but according to the Bulgarian prime minister, it’s not.

They don’t seem to be changing the vaccine as new variants arrive. So, raising the prices doesn’t seem to be linked to research issues and as for the new production facilities, surely those didn’t cost billions.

Canada and COVID-19 money

Talking about money, Canada has a COVDI-19 billionaire according to a December 23, 2020 article (Meet The 50 Doctors, Scientists And Healthcare Entrepreneurs Who Became Pandemic Billionaires In 2020) by Giacomo Tognini for Forbes.

I have a bit more about Carl Hansen (COVID-19 billionaire) and his company, AbCellera, in my December 30, 2020 posting.

I wonder how much the Canadian life sciences community has to do with Canada’s hesitancy over a COVID-19 vaccine patent rights waiver.